{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:20:06Z","timestamp":1791091206698,"version":"4.1.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"3","content-domain":{"domain":["lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.lungcan.2014.03.006","type":"journal-article","created":{"date-parts":[[2014,3,18]],"date-time":"2014-03-18T04:17:39Z","timestamp":1395116259000},"page":"271-274","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"title":["Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma"],"prefix":"10.1016","volume":"84","author":[{"given":"Marjorie G.","family":"Zauderer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha L.","family":"Kass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camelia S.","family":"Sima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle S.","family":"Ginsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee M.","family":"Krug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.lungcan.2014.03.006_bib0005","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.lungcan.2014.03.006_bib0010","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.lungcan.2008.04.001","article-title":"The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma","volume":"63","author":"Stebbing","year":"2009","journal-title":"Lung Cancer"},{"issue":"9625","key":"10.1016\/j.lungcan.2014.03.006_bib0015","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(08)60727-8","article-title":"Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial","volume":"371","author":"Muers","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2014.03.006_bib0020","article-title":"Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma","author":"Zucali","year":"2013","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2014.03.006_bib0025","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1002\/(SICI)1097-0142(19990615)85:12<2577::AID-CNCR13>3.0.CO;2-S","article-title":"A phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group","volume":"85","author":"van Meerbeeck","year":"1999","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2014.03.006_bib0030","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/annonc\/mdi187","article-title":"Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma","volume":"16","author":"Manegold","year":"2005","journal-title":"Ann Oncol"},{"issue":"2\u20133","key":"10.1016\/j.lungcan.2014.03.006_bib0035","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0169-5002(00)00166-5","article-title":"Gemcitabine for malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B","volume":"31","author":"Kindler","year":"2001","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2014.03.006_bib0040","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/sj.bjc.6600505","article-title":"A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma","volume":"87","author":"Nowak","year":"2002","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2014.03.006_bib0045","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/sj.bjc.6600118","article-title":"Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma","volume":"86","author":"van Haarst","year":"2002","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2014.03.006_bib0050","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.1999.17.1.25","article-title":"Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study","volume":"17","author":"Byrne","year":"1999","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.lungcan.2014.03.006_bib0055","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/cncr.23337","article-title":"Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma","volume":"112","author":"Zucali","year":"2008","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2014.03.006_bib0060","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.lungcan.2014.03.006_bib0065","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0959-8049(11)70098-3","article-title":"VANTAGE 014: vorinostat (V) in patients with advanced malignant pleural mesothelioma (MPM) who have failed prior pemetrexed and either cisplatin or carboplatin therapy: a phase III, randomized, double-blind, placebo-controlled trial","volume":"47","author":"Krug","year":"2011","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2014.03.006_bib0070","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/path.3979","article-title":"BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma","volume":"227","author":"Busacca","year":"2012","journal-title":"J Pathol"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500214001275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500214001275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T14:57:38Z","timestamp":1565276258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500214001275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0169500214001275"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2014.03.006","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2014.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}